18 Jul Profluent
Hilary Eaton, Ph.D., Chief Business Officer
Oct. 6 | 5:30pm | FLW Ballroom G
Emeryville, CA
(Private)
Profluent is an AI-first protein design company that aims to make biology programmable. Whereas biological discovery has largely depended on chance or traditional engineering approaches, Profluent is finally changing this with an AI-powered platform that learns from the underlying “grammar” of natural protein sequences at scale to design new proteins with specific functions for medicine, climate, and sustainable agriculture.
Profluent made history as the first company to edit the human genome with an AI-created, open-source gene editor, OpenCRISPR-1. It has since released one of the largest AI biological models to-date, which was used to design an ultra-compact gene editor and redesign 20 blockbuster antibody drugs.
As Profluent redefines traditional drug discovery, it is also transforming biopharma partnerships with a flexible model – enabling collaborators to license bespoke proteins (such as antibodies for BioSpecifics or gene editors for therapeutics) or tap into its foundational technology platform.
